Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Preferred Stock and Changes in Stockholders??? Deficit (Unaudited)

v3.24.2.u1
Condensed Consolidated Statements of Preferred Stock and Changes in Stockholders’ Deficit (Unaudited) - USD ($)
$ in Thousands
Total
AlmataBio Transaction
Series C Preferred Stock
Series C Preferred Stock
AlmataBio Transaction
Series C Preferred Stock
Private Placement
Series D Preferred Stock
Series D Preferred Stock
Private Placement
Series E Preferred Stock
Series E Preferred Stock
Private Placement
Common stock
Common stock
AlmataBio Transaction
Additional paid-in capital
Additional paid-in capital
AlmataBio Transaction
Accumulated deficit
Balance at the beginning (in shares) at Dec. 31, 2022 [1]                   39,294        
Balance at the beginning at Dec. 31, 2022 $ (10,915)                     $ 292,909 [1]   $ (303,824)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                            
Issuance of shares of common stock and warrants in underwritten public offering, net (in shares) [1]                   15,709        
Issuance of common stock and warrants in underwritten public offering, net 13,748                     13,748 [1]    
Issuance of common shares pursuant to ATM Program, net (in shares) [1]                   8,520        
Issuance of common shares pursuant to ATM Program, net 6,531                     6,531 [1]    
Retirement of common shares in exchange for pre-funded warrants (in shares) [1]                   (5,417)        
Retirement of common shares in exchange for pre-funded warrants (3,640)                     (3,874) [1]   234
Issuance of pre-funded warrants in exchange for retirement of common shares 3,640                     3,640 [1]    
Exercise of pre-funded warrants for common shares (in shares) [1]                   301        
Shares purchased through employee stock purchase plan (in shares) [1]                   82        
Shares purchased through employee stock purchase plan 67                     67 [1]    
Stock-based compensation 1,748                     1,748 [1]    
Net Income (loss) (18,148)                         (18,148)
Balance at the end (in shares) at Jun. 30, 2023 [1]                   58,489        
Balance at the end at Jun. 30, 2023 (6,969)                     314,769 [1]   (321,738)
Balance at the beginning (in shares) at Mar. 31, 2023 [1]                   55,003        
Balance at the beginning at Mar. 31, 2023 (6,267)                     307,512 [1]   (313,779)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                            
Issuance of common shares pursuant to ATM Program, net (in shares) [1]                   8,520        
Issuance of common shares pursuant to ATM Program, net 6,531                     6,531 [1]    
Retirement of common shares in exchange for pre-funded warrants (in shares) [1]                   (5,417)        
Retirement of common shares in exchange for pre-funded warrants (3,640)                     (3,874) [1]   234
Issuance of pre-funded warrants in exchange for retirement of common shares 3,640                     3,640 [1]    
Exercise of pre-funded warrants for common shares (in shares) [1]                   301        
Shares purchased through employee stock purchase plan (in shares) [1]                   82        
Shares purchased through employee stock purchase plan 67                     67 [1]    
Stock-based compensation 893                     893 [1]    
Net Income (loss) (8,193)                         (8,193)
Balance at the end (in shares) at Jun. 30, 2023 [1]                   58,489        
Balance at the end at Jun. 30, 2023 $ (6,969)                     314,769 [1]   (321,738)
Balance at the beginning (in shares) at Dec. 31, 2023     0     0   0            
Balance at the beginning at Dec. 31, 2023     $ 0     $ 0   $ 0            
Increase (Decrease) in Temporary Equity [Roll Forward]                            
Issuance of stock (in shares)       2,412 19,946   1   1          
Issuance of stock       $ 11,457                    
Balance at the end (in shares) at Jun. 30, 2024 22,360   22,358     1   1            
Balance at the end at Jun. 30, 2024 $ 11,457   $ 11,457     $ 0   $ 0            
Balance at the beginning (in shares) at Dec. 31, 2023 801,746                 801,746        
Balance at the beginning at Dec. 31, 2023 $ 7,304                 $ 1   342,437   (335,134)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                            
Impact of reverse split fractional share round-up (in shares)                   60,779        
Issuance of common stock and preferred stock as part of Almata Transaction (in shares)                     171,605      
Issuance of common stock pursuant to Almata Transaction   $ 815                     $ 815  
Stock-based compensation 1,100                     1,100    
Net Income (loss) $ (22,827)                         (22,827)
Balance at the end (in shares) at Jun. 30, 2024 1,034,130                 1,034,130        
Balance at the end at Jun. 30, 2024 $ (13,608)                 $ 1   344,352   (357,961)
Balance at the beginning (in shares) at Mar. 31, 2024 22,360                          
Balance at the beginning at Mar. 31, 2024 $ 11,457                          
Balance at the end (in shares) at Jun. 30, 2024 22,360   22,358     1   1            
Balance at the end at Jun. 30, 2024 $ 11,457   $ 11,457     $ 0   $ 0            
Balance at the beginning (in shares) at Mar. 31, 2024                   1,034,130        
Balance at the beginning at Mar. 31, 2024 (112,542)                 $ 1   343,881   (456,424)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                            
Stock-based compensation 471                     471    
Net Income (loss) $ 98,463                         98,463
Balance at the end (in shares) at Jun. 30, 2024 1,034,130                 1,034,130        
Balance at the end at Jun. 30, 2024 $ (13,608)                 $ 1   $ 344,352   $ (357,961)
[1] Amounts for prior periods presented have been retroactively adjusted to reflect the 1-for-240 reverse stock split effected on December 28, 2023. See Note 1 for details.